Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Carboplatin + FKB238 + Paclitaxel |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
FKB238 | HD204|BP102|SCT501 | VEGFA Antibody 4 | FKB238 is a biosimilar to Avastin (bevacizumab), which is a VEGFA targeted antibody (J Clin Oncol 35, 2017 (suppl; abstr e14007)). | |
Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02810457 | Phase III | Carboplatin + FKB238 + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel | Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer (AVANA) | Completed | USA | TUR | ROU | POL | ITA | HUN | HRV | GRC | ESP | DEU | BGR | 13 |